A needle-free vaccine patch might higher battle COVID-19 variants, resembling Omicron and Delta, than a standard needle vaccine in keeping with a University of Queensland examine in mice.
The analysis, carried out in partnership with Brisbane biotechnology firm Vaxxas, examined the Hexapro SARS-CoV-2 spike vaccine utilizing the Vaxxas high-density microarray patch (HD-MAP) know-how, and the outcomes discovered the patch was far more practical at neutralising COVID-19 variants.
UQ’s Dr Christopher McMillan stated the vaccine patch appeared to counteract new variants extra successfully than the present SARs-CoV-2 vaccine delivered by injection.
“The high-density microarray patch is a vaccine supply platform that exactly delivers the vaccine into the layers of the pores and skin that are wealthy in immune cells,” Dr McMillan stated.
“We discovered that vaccination through a patch was roughly 11 occasions more practical at combatting the Omicron variant when put next with the identical vaccine administered through a needle.”
He stated the outcomes prolonged additional than simply the Hexapro vaccine.
“Thus far, each vaccine kind we’ve examined by means of the patch, together with subunit, DNA, inactivated virus and conjugate produces superior immune responses in comparison with conventional needle vaccination strategies,” he stated.
UQ’s Dr David Muller stated currently-available vaccines might not be as efficient due to the continually rising new variants of COVID-19, and this has left researchers at a crossroads.
“This decreased effectiveness was highlighted by the Omicron variant, which comprises over 30 mutations within the spike protein,” Dr Muller stated.
“The big variety of mutations have given the virus the flexibility to evade the immune responses generated by the present vaccines.
“Nevertheless, the patch know-how has the potential to supply a brand new – and more practical – weapon in our arsenal, at a time the place new variants are mutating at a speedy price.
“The patches should not solely more practical in opposition to rising variants however are additionally far simpler to manage than needle-based vaccines.
“However, it is very important stress that present vaccines are nonetheless an efficient means of combatting critical sickness and illness from this virus and it isn’t the time to drop our guard.”
Vaxxas CEO, David Hoey stated that is additional proof of the game-changing potential the know-how platform might have in serving to nations higher reply to international well being emergencies, like the present and future pandemics.
“We’re persevering with to scale-up our manufacturing capabilities and speed up product improvement in preparation for large-scale scientific trials,” he stated.
“This consists of building of our first manufacturing facility in Brisbane to assist the transition to commercialising of our HD-MAP vaccine candidates, together with a Hexapro COVID-19 patch.”
The analysis has been revealed in Vaccine.
The examine was funded by an Advance Queensland Trade Analysis Fellowship awarded to Dr David Muller.